Delivery Order SPE2DB22D3004-SPE2DB25FQS76
Award Date
5/16/25
Potential Completion Date
5/19/25
Potential Value
$2.1K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract, valued at $69,524.40, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of September 11, 2024. The contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,182.96, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The contract is a Delivery Order under a larger...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distribution company Amerisourcebergen Corporation, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine to the Defense Logistics Agency (DLA). The $1,577.28 fixed-price delivery order contract has a completion date of May 22, 2024. This award is associated with Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $16,849.60 and is a Firm Fixed Price Delivery Order, awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 14, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, with a ceiling value of $60,531.96. This is a delivery order contract, with a firm-fixed price pricing type, and the ultimate completion date is September 13, 2022. The contract is not designated with any set-aside...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $2,039.05 and a completion date of November 20, 2024. This is a delivery order contract with a firm fixed price pricing type. The award is not associated with a set-aside program. Amerisourcebergen Drug...
This federal contract award is for the delivery of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract, with a ceiling value of $19,716.00, was awarded by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued up to $999,999,999.00 through December 31, 2025. This...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The contract, valued at $3,595.57, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine. The delivery order falls under a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,577.28, was awarded to AmerisourceBergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp...
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...